SCHEMBL1077186

SCHEMBL1077186

Cc1ccc(C(=O)Nc2cc(C(F)(F)F)ccn2)cc1-c1cc2cnc(NC(=O)C3CC3)nc2c(-c2ccc(F)nc2)c1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 13/20 0.47
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42
BTK Q06187 5/20 0.41
BRAF P15056 1/20 0.41
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
YES1 P07947 1/20 0.41
LYN P07948 1/20 0.41
FGR P09769 1/20 0.41
SRC P12931 1/20 0.41
CSK P41240 1/20 0.41
TEC P42680 1/20 0.41
TXK P42681 1/20 0.41
FRK P42685 1/20 0.41
BLK P51451 1/20 0.41
BMX P51813 1/20 0.41
ITK Q08881 1/20 0.41
KCNH2 Q12809 1/20 0.41
PTK6 Q13882 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1079625 0.92 ABL1 (0.46) ABL1GSK3AGSK3BBRAF
SCHEMBL1077797 0.90 BTK (0.42) ABL1BTKBRAFLCKSRC
SCHEMBL1079128 0.90 ABL1 (0.47) ABL1GSK3AGSK3BBRAFSRC
SCHEMBL1077238 0.89 BTK (0.42) ABL1BTKBRAFLCKSRC
SCHEMBL1076926 0.89 LCK (0.48) ABL1BTKBRAFLCKFYN
SCHEMBL1077835 0.87 ABL1 (0.47) ABL1GSK3AGSK3BBRAFLCK
SCHEMBL1082637 0.83 ABL1 (0.55) ABL1BTKBRAFLCKSRC
SCHEMBL1079336 0.81 LCK (0.49) ABL1BTKBRAFLCKSRC
SCHEMBL1079743 0.81 BRAF (0.42) ABL1BTKBRAFLCKSRC
SCHEMBL1077787 0.81 LCK (0.53) ABL1BTKBRAFLCKSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2269993-B1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2013-02-27 EP disclosed
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed
EP-2269993-A1 2-AMINOQUINAZOLINE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 ABL1 47/4885GSK3A 3643/4885GSK3B 3859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.